Who we are
Part of the Pharmacells™ group of companies and brands, we are experts in the invention, development and commercialisation of new biotechnology and life sciences products.
Our product range is multi-patented and available all over the world.
We are based in the United Kingdom and operate from our own, fully UK regulatory compliant laboratory facilities.
We work to cGMP standards under Human Tissue Authority Licence no. 22622 and are therefore fully compliant with the EUCTD - European Cells and Tissues Directives.
What we do
Our in-house team of experienced scientists work in collaboration with some of the world's most respected institutions and biotechnology firms to create new products, particularly in the cell biology space.
We're most well-known for our Oristem® adult stem cell banking product range which is revolutionising the way that stem cells are stored for adults around the world.
We also work with stem cells to develop new types of personalised cell therapies and it is that work that lead us to find new ways to improve cell viability.
How we're different
We have taken a concept that is well-known (magnetic separation) but that had only demonstrated variable quality results and made it more reliable and feasible for use within modern science.
Product development took place in the UK over a number of years and has culminated in a simple, cost-effective process that opens up debris removing nanotechnology to all.
We have companies big and small, academic institutions, research institutions and government/fedaral agancies using our product to improve their work every day.
Drop us a line and we can tell you a little more about who uses the products and how we have helped improve their project outcomes.
ClioCell™ is an ex-vivo device for removal of dying and dead cells, improving viability and quality of cell populations and their subsequent productivity. Studies using Cliocell™ to remove apoptotic and necrotic cells and debris from culture systems have shown a demonstrable improvement in viable cell numbers following removal of inhibitory dead cells - significantly accelerating revival of cells after cryopreservation.
- Enhanced growth and productivity of multiple cell types
- Improved screen and assay quality following removal of degraded macromolecules
- Faster recovery and increased secretion of proteins post-thaw
- Improved purity, consistency and efficacy of cell cultures therefore lower Cost Of Goods (COGs)
- Cell culture expansion times reduced
- cGMP grade available